IL145034A0 - Method for validating/invalidating target(s) and pathways - Google Patents
Method for validating/invalidating target(s) and pathwaysInfo
- Publication number
- IL145034A0 IL145034A0 IL14503400A IL14503400A IL145034A0 IL 145034 A0 IL145034 A0 IL 145034A0 IL 14503400 A IL14503400 A IL 14503400A IL 14503400 A IL14503400 A IL 14503400A IL 145034 A0 IL145034 A0 IL 145034A0
- Authority
- IL
- Israel
- Prior art keywords
- invalidating
- validating
- pathways
- target
- invalidating target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12295099P | 1999-03-05 | 1999-03-05 | |
PCT/US2000/005643 WO2000051621A1 (en) | 1999-03-05 | 2000-03-02 | Method for validating/invalidating target(s) and pathways |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145034A0 true IL145034A0 (en) | 2002-06-30 |
Family
ID=22405857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14503400A IL145034A0 (en) | 1999-03-05 | 2000-03-02 | Method for validating/invalidating target(s) and pathways |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1165093A4 (en) |
JP (1) | JP2002537792A (en) |
KR (1) | KR20020068262A (en) |
CN (1) | CN1348376A (en) |
AU (1) | AU3512300A (en) |
BR (1) | BR0009247A (en) |
CA (1) | CA2366055A1 (en) |
IL (1) | IL145034A0 (en) |
MX (1) | MXPA01008870A (en) |
WO (1) | WO2000051621A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2400206A1 (en) | 2000-02-17 | 2001-08-23 | Cv Therapeutics, Inc. | Method for identifying and using a2b adenosine receptor antagonists to mediate mammalian cell proliferation |
DE10346487A1 (en) * | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Process for the preparation of a cell and / or tissue and / or disease phase specific drug |
AU2007214547B2 (en) | 2006-02-13 | 2012-09-20 | Monsanto Technology Llc | Selecting and stabilizing dsRNA constructs |
US7741446B2 (en) | 2006-08-18 | 2010-06-22 | Armagen Technologies, Inc. | Fusion antibodies that cross the blood-brain barrier in both directions |
DE102007021443A1 (en) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using NT-proET-1 |
CA3184105A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
US9533055B2 (en) | 2009-03-18 | 2017-01-03 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins |
SI2485761T1 (en) | 2009-10-09 | 2019-05-31 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
CN102169121B (en) * | 2010-02-25 | 2013-12-04 | 北京诺赛基因组研究中心有限公司 | New application of human kinase SBK1 (SH3-binding domain kinase 1) |
AU2012346448B2 (en) | 2011-12-02 | 2017-09-14 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
WO2015009961A1 (en) * | 2013-07-19 | 2015-01-22 | Armagen Technologies, Inc. | Compositions and methods related to structures that cross the blood brain barrier |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
SI3093022T1 (en) | 2015-05-15 | 2019-12-31 | Sterna Biologicals Gmbh & Co. Kg | Gata-3 inhibitors for use in the treatment of th2-driven asthma |
CN114480406B (en) * | 2021-09-16 | 2024-01-30 | 广东翠点生物科技有限公司 | IL-1 signal path response element and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
WO2000042178A2 (en) * | 1999-01-13 | 2000-07-20 | Dupont Pharmaceuticals Company | Antagonist blockade of crf2 receptors for the treatment of psy chiatric disorders and the use of chimeric antisense oligonucleotides in in vivo cns studies of gene function |
-
2000
- 2000-03-02 JP JP2000602288A patent/JP2002537792A/en not_active Withdrawn
- 2000-03-02 WO PCT/US2000/005643 patent/WO2000051621A1/en not_active Application Discontinuation
- 2000-03-02 CN CN00806759A patent/CN1348376A/en active Pending
- 2000-03-02 KR KR1020017011238A patent/KR20020068262A/en not_active Application Discontinuation
- 2000-03-02 BR BR0009247-9A patent/BR0009247A/en not_active IP Right Cessation
- 2000-03-02 IL IL14503400A patent/IL145034A0/en unknown
- 2000-03-02 CA CA002366055A patent/CA2366055A1/en not_active Abandoned
- 2000-03-02 EP EP00913730A patent/EP1165093A4/en not_active Withdrawn
- 2000-03-02 AU AU35123/00A patent/AU3512300A/en not_active Abandoned
- 2000-03-02 MX MXPA01008870A patent/MXPA01008870A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2002537792A (en) | 2002-11-12 |
CN1348376A (en) | 2002-05-08 |
WO2000051621A1 (en) | 2000-09-08 |
MXPA01008870A (en) | 2004-08-12 |
BR0009247A (en) | 2001-11-20 |
EP1165093A1 (en) | 2002-01-02 |
AU3512300A (en) | 2000-09-21 |
CA2366055A1 (en) | 2000-09-08 |
KR20020068262A (en) | 2002-08-27 |
EP1165093A4 (en) | 2002-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9903124D0 (en) | An authentication method | |
GB2342743B (en) | Verification method | |
GB9918348D0 (en) | Location finding system and method | |
HK1035243A1 (en) | Method and apparatus for executing prefetch instructions. | |
IL136155A0 (en) | Data processing method | |
GB9911956D0 (en) | Electrosurgery system and method | |
HK1042357A1 (en) | Viewpoint control device and method | |
AU1674702A (en) | Implanted sensor processing system and method | |
GB0118394D0 (en) | Radiation treatment system and method | |
EP1260051A4 (en) | System and method for secure electronic fund transfers | |
EP1146912A4 (en) | Method for improved radiation therapy | |
HK1048373A1 (en) | An access control method | |
IL145034A0 (en) | Method for validating/invalidating target(s) and pathways | |
PL343990A1 (en) | Method fo carrying out an aldolic condensation | |
GB9900070D0 (en) | Control method | |
IL149270A0 (en) | System and method for secure electronic transactions | |
PL345207A1 (en) | Gene therapy method | |
GB0229834D0 (en) | Target and method | |
EP1079335A4 (en) | Bill processor and its controlling method | |
EP1053349A4 (en) | Methods for identifying therapeutic targets | |
GB0026109D0 (en) | An analysis method | |
SG108228A1 (en) | Accurate processing through procedure validation in software controlled environment | |
GB9916569D0 (en) | Apparatus and method for sensing metal ions | |
IL150268A0 (en) | Method and system for detecting radiation | |
GB9928112D0 (en) | Electronic payment method |